Lisa Patel, PhD, CPH
Public Health & Epidemiology Reviewer
Want more health insights like this?
No spam. Unsubscribe anytime.
Our process
Lisa Patel, PhD, CPH
Public Health & Epidemiology Reviewer
No spam. Unsubscribe anytime.
Published: January 12, 2026 • 16 min read
Every medication has side effects. What matters is whether you know what to expect, how likely each one is, and what to do about it. I have seen too many people panic over things that are normal and predictable, and not enough people take action on the side effects that actually need attention.
This is a side-effect-by-side-effect breakdown based on the clinical trial data, the FDA prescribing information, and what clinicians report seeing in practice. No sugarcoating, no fear-mongering.
Nausea is the side effect everyone asks about first, and for good reason. It is the most commonly reported adverse event in every major GLP-1 trial.
In the STEP 1 trial (semaglutide 2.4 mg), 44.2% of participants in the drug group reported nausea, compared to 17.4% on placebo. In SURMOUNT-1 (tirzepatide), the rates were 24-33% depending on the dose, somewhat lower than semaglutide.
Here is what the numbers do not tell you: intensity and duration. Most nausea is mild to moderate. In STEP 1, only 1.6% of participants discontinued the drug due to nausea. That means for the vast majority of people who experience it, the nausea is tolerable.
Nausea follows a predictable pattern. It typically appears within the first few days of starting the medication or increasing the dose. It peaks during week 1-2 at each new dose level. It gradually fades over 4-8 weeks as your body adjusts. Then it comes back when you titrate up to the next dose. And the cycle repeats.
By the time you reach your maintenance dose and have been there for a month or two, most people find the nausea has resolved almost completely. The dose escalation period is the worst of it.
Nausea gets the attention, but GLP-1 medications affect the entire gastrointestinal tract. Here is the full picture from the clinical trial data.
| Side Effect | Semaglutide 2.4 mg (STEP 1) | Tirzepatide 15 mg (SURMOUNT-1) | Placebo |
|---|---|---|---|
| Nausea | 44.2% | 33.3% | 17.4% |
| Diarrhea | 30.0% | 25.4% | 15.7% |
| Vomiting | 24.8% | 12.2% | 6.2% |
| Constipation | 24.2% | 20.9% | 10.5% |
| Abdominal pain | 15.2% | 14.0% | 10.2% |
| Dyspepsia (indigestion) | 8.6% | 9.2% | 3.8% |
| GERD/acid reflux | 5.0% | 5.6% | 1.8% |
| Flatulence | 4.2% | 4.1% | 2.8% |
A few things stand out. First, notice the placebo rates. Nausea was reported by 17% of people taking a placebo. That is partly because GI complaints are incredibly common in general, and partly the nocebo effect (expecting side effects makes you more likely to experience them).
Second, diarrhea and constipation are nearly equally common, which seems contradictory until you understand that GLP-1 medications alter gut motility in complex ways. Some people experience one, some the other, and some alternate between the two, especially during dose changes.
Third, vomiting rates are notably lower with tirzepatide (12.2%) than semaglutide (24.8%). If nausea and vomiting are your primary concern, this is worth discussing with your prescriber.
Constipation on GLP-1 medications is a direct result of slowed gastric emptying extending into slower transit throughout the entire GI tract. If food moves through your stomach more slowly, everything downstream slows too.
Practical fixes: increase fiber intake gradually (too much too fast will make things worse), drink at least 2 liters of water daily, and walk for 15-20 minutes after meals. If those do not work, an over-the-counter osmotic laxative like polyethylene glycol (Miralax) is safe for daily use. Stool softeners like docusate (Colace) are another option.
Do not ignore constipation for weeks. Severe cases can progress to bowel obstruction, which is a medical emergency. If you have not had a bowel movement in 3-4 days, call your doctor.
The term "Ozempic face" went viral in 2023 and has caused more anxiety than it probably should have. What people call "Ozempic face" is not a drug-specific side effect. It is what happens when anyone loses 15-25% of their body weight relatively quickly: the fat pads in the face deflate, and the skin (especially in people over 40 whose skin has less elasticity) sags.
The same thing happens after bariatric surgery. It happens after aggressive dieting. It happens anytime you lose a lot of weight fast. The fact that it has a catchy name attached to a specific drug makes it seem unique to that drug, but it is not.
The real concern is not the cosmetic facial change. It is what that facial change represents: overall lean mass loss. When you see dramatic facial wasting, the person has lost significant muscle mass throughout their body, not just facial fat.
Data from STEP trials and body composition substudy analyses consistently show that approximately 25-40% of weight lost on semaglutide is lean body mass. In a person who loses 40 pounds, that means 10-16 pounds of muscle gone along with the fat.
This is not inevitable. A 2024 study in JAMA Network Open found that participants who combined semaglutide with a structured resistance training program and high-protein diet (1.6 g/kg/day) lost significantly less lean mass than those on medication alone. The resistance training group preserved roughly 80% of their lean mass compared to about 65% in the medication-only group.
The prescription is clear: lift weights and eat protein. It will not fully prevent lean mass loss, but it dramatically reduces it. If you want to figure out exactly how much protein you should be targeting, our GLP-1 nutrition calculator personalizes recommendations based on your weight, activity level, and specific medication.
This one is real and underappreciated. Rapid weight loss increases the risk of gallstones, and GLP-1 medications may add to that risk through their effects on gallbladder motility.
In the STEP 1 trial, gallbladder-related disorders (gallstones, cholecystitis, biliary colic) occurred in 2.6% of the semaglutide group versus 1.2% in the placebo group. In SURMOUNT-1, rates were similar, around 0.6-1.7% depending on the dose.
Those percentages sound small, but in a population of millions of people taking these drugs, that translates to tens of thousands of gallbladder events. Some require surgery (cholecystectomy).
The mechanism is straightforward. When you lose weight rapidly, your liver secretes more cholesterol into bile. Simultaneously, the gallbladder is not emptying as efficiently because of the GLP-1 effect on smooth muscle motility. More cholesterol plus slower emptying equals higher gallstone risk.
Warning signs include: sudden sharp pain in the right upper abdomen (especially after eating fatty foods), pain that radiates to the right shoulder or back, nausea and vomiting that feel different from your baseline GLP-1 nausea, and fever. If you experience these, contact your doctor promptly.
Risk factors that increase your chances: being female (gallstones are 2-3 times more common in women), rapid weight loss (more than 1.5 kg per week), history of gallstones, and being over age 40.
The pancreatitis concern has been debated since the early days of GLP-1 medications. It is a legitimate topic. But the data is far more nuanced than the fear-mongering suggests.
First, the background. GLP-1 receptors exist on pancreatic cells. Early animal studies showed potential changes in pancreatic tissue. Some case reports of pancreatitis in patients taking liraglutide (an older GLP-1 drug) raised alarm.
Here is what the large-scale human data shows. In the STEP trials, acute pancreatitis occurred in about 0.2% of participants on semaglutide versus 0.1% on placebo. In the LEADER cardiovascular outcomes trial (liraglutide, over 9,000 patients followed for nearly 4 years), there was no statistically significant increase in pancreatitis risk.
A 2023 meta-analysis published in Diabetes Care that pooled data from multiple GLP-1 trials covering more than 150,000 patient-years of exposure found no statistically significant increase in pancreatitis risk compared to placebo.
My read: there is likely a very small increase in risk that is difficult to detect even in large trials because pancreatitis is uncommon at baseline. The risk does not approach the level that should prevent people from taking these medications, unless they have a history of pancreatitis, which is listed as a contraindication.
If you experience severe abdominal pain that radiates to your back, does not improve with position changes, and is accompanied by nausea and vomiting, stop the medication and go to the emergency room. Acute pancreatitis requires immediate medical evaluation.
Every GLP-1 medication carries a black box warning about thyroid C-cell tumors. This is the scariest-sounding thing in the prescribing information, and it deserves a careful look.
The background: in rodent studies, semaglutide and tirzepatide caused dose-dependent increases in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). The doses used were significantly higher relative to body weight than human doses, and rodents were exposed for their entire lifetimes (2 years, which is roughly equivalent to a human lifetime).
Rodents have far more GLP-1 receptors on their thyroid C-cells than humans do. This is a well-documented species difference. It means the rat findings may not translate to humans at all.
What does the human data show? A 2024 analysis published in The BMJ looked at semaglutide use in over 300,000 patients with a median follow-up of about 3 years and found no signal for increased thyroid cancer risk. A separate Scandinavian study using national registry data from Denmark, Norway, and Sweden that tracked GLP-1 use over multiple years also found no increased risk of MTC.
But there is a critical caveat. MTC is extremely rare (about 500-1,000 new cases per year in the US). Even a doubling of risk might take decades to become detectable in epidemiological studies. We simply do not have 20-year data on semaglutide use in humans.
This is why the contraindication for personal or family history of MTC or MEN2 exists. If you are already at elevated risk for MTC, the theoretical concern warrants avoiding these drugs. For everyone else, the current evidence is reassuring but not yet definitive. This is one of those situations where the honest answer is that we are still watching.
Redness, swelling, or itching at the injection site occurred in about 3-5% of trial participants. These are almost always mild and self-limiting. Rotating injection sites (abdomen, thigh, upper arm) minimizes recurrence.
Reported in about 14% of semaglutide users versus 10% on placebo. Often related to dehydration or reduced caloric intake. If you went from eating 2,500 calories to 1,400 calories in a week because your appetite vanished, a headache is not surprising. Ensure adequate hydration and do not let your calorie intake drop below 1,200 (women) or 1,500 (men) without medical supervision.
Fatigue is common in the first few weeks and again during dose increases. It is partly metabolic (your body is adjusting to lower caloric intake) and partly because nausea is draining. It typically resolves as side effects stabilize.
This has been widely reported anecdotally, though clinical trial data is limited. Rapid weight loss of any kind can trigger telogen effluvium, a temporary shedding caused by the physiological stress of significant calorie restriction. It typically begins 2-4 months after starting the medication and resolves within 6-12 months as the body adjusts to its new weight. Ensuring adequate protein, iron, zinc, and biotin intake can help.
The European Medicines Agency reviewed reports of suicidal ideation and self-harm in GLP-1 users in 2023. Their conclusion: no causal link was established. The FDA conducted a similar review and reached the same conclusion in 2024. However, ongoing monitoring continues. If you notice new or worsening depression, anxiety, or suicidal thoughts while taking a GLP-1 medication, report it to your doctor immediately.
GLP-1 medications slow gastric emptying by design. In rare cases, this can become pathologically slow (gastroparesis). Reports of severe gastroparesis requiring hospitalization have emerged in post-marketing surveillance. The risk appears to be higher in people who already have some degree of impaired gastric motility (common in long-standing diabetes) and in those taking the highest doses.
There have also been concerns about food retained in the stomach during general anesthesia in patients taking GLP-1s. The American Society of Anesthesiologists released guidance in 2023 recommending that patients hold their GLP-1 medication for at least one week before any elective surgery requiring general anesthesia. Tell your anesthesiologist that you are taking a GLP-1 drug before any procedure.
| Side Effect | When It Peaks | What Helps |
|---|---|---|
| Nausea | Week 1-2 of each new dose | Small meals, avoid fatty foods, ginger, stay upright after eating |
| Vomiting | Week 1-2 of each new dose | Smaller portions, bland foods, slow titration, ondansetron if prescribed |
| Constipation | Ongoing, especially at higher doses | Fiber, 2+ liters water daily, walking, Miralax if needed |
| Diarrhea | First 4-6 weeks | Avoid sugar alcohols and high-fat foods, stay hydrated, usually self-resolving |
| Headache | First 2-4 weeks | Hydration, adequate calorie intake, OTC pain relief |
| Fatigue | First 2-4 weeks and during dose increases | Ensure adequate calories and protein, prioritize sleep, usually temporary |
| Hair loss | Months 2-4 of treatment | Adequate protein, iron, zinc, biotin; temporary and self-resolving |
| Injection site reactions | First few injections | Rotate sites, inject at room temperature |
| GERD/reflux | Ongoing | Small meals, avoid eating before bed, elevate head of bed, antacids if needed |
Most GLP-1 side effects are manageable at home. But some situations require prompt medical attention. Do not wait on these.
There are a few things that do not show up in clinical trial adverse event tables but matter in real life.
Your relationship with food will change. For many people, eating was a source of pleasure, comfort, or social connection. When the medication removes the drive to eat, some people experience a form of grief. Food stops being exciting. Meals become obligatory. This is not depression in the clinical sense, but it is an adjustment that catches people off guard.
Social eating becomes awkward. When your friends order full entrees and you can barely finish an appetizer, it changes the dynamic. When you cannot have that second drink because your stomach cannot handle it, people notice. Some people find this isolating.
Alcohol tolerance drops significantly. Multiple patient reports and emerging research suggest that GLP-1 medications reduce alcohol cravings and tolerance. A 2023 study in The Journal of Clinical Endocrinology & Metabolism confirmed that semaglutide reduces alcohol intake in people with alcohol use disorder. Even without a formal diagnosis, many patients report needing significantly less alcohol to feel its effects, and hangovers become worse. Be cautious with alcohol, especially in the early months.
The "last meal" phenomenon. Some people find that their ability to enjoy certain foods disappears entirely. Foods they used to love become nauseating. This is usually temporary, but in some cases, specific food aversions persist for the duration of treatment.
Side effects are the cost of entry with any medication. The question is always whether the benefits justify the costs. For GLP-1 medications, the calculus looks like this: you are trading GI discomfort (mostly temporary) and the ongoing costs of the medication for 15-22% weight loss, significant cardiometabolic improvement, and a 20% reduction in cardiovascular events.
For most people with clinically significant obesity, that trade-off is favorable. But it is a trade-off, and you should go in with realistic expectations about what the first few months will feel like.
The single most important thing you can do to reduce side effects and improve outcomes is to titrate slowly, eat adequate protein, stay hydrated, and do resistance training. If you want personalized nutrition targets for your specific medication, use our GLP-1 nutrition calculator to get started.
And if side effects become unmanageable, tell your doctor. Slower titration, dose adjustment, or switching to a different medication in the class are all valid options. Suffering in silence is not required.